106 related articles for article (PubMed ID: 2080254)
21. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.
Schindlbeck C; Kampik T; Janni W; Rack B; Jeschke U; Krajewski S; Sommer H; Friese K
Breast Cancer Res; 2005; 7(6):R1174-85. PubMed ID: 16457698
[TBL] [Abstract][Full Text] [Related]
22. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
Lavertu P; Adelstein DJ; Myles J; Secic M
Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
[TBL] [Abstract][Full Text] [Related]
23. Comparison between Ki-67 index and S-phase fraction on fine-needle aspiration samples from breast carcinoma.
Bozzetti C; Nizzoli R; Camisa R; Guazzi A; Ceci G; Cocconi G; Mazzini G; Naldi N
Cancer; 1997 Oct; 81(5):287-92. PubMed ID: 9349516
[TBL] [Abstract][Full Text] [Related]
24. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
Gentilini O; Masullo M; Rotmensz N; Peccatori F; Mazzarol G; Smeets A; Simsek S; De Dosso S; Veronesi P; Intra M; Zurrida S; Viale G; Goldhirsch A; Veronesi U
Eur J Surg Oncol; 2005 Apr; 31(3):232-6. PubMed ID: 15780556
[TBL] [Abstract][Full Text] [Related]
26. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
[TBL] [Abstract][Full Text] [Related]
27. Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer.
Oshima CT; Iriya K; Forones NM
Neoplasma; 2005; 52(5):420-4. PubMed ID: 16151588
[TBL] [Abstract][Full Text] [Related]
28. The Ki-67 protein: from the known and the unknown.
Scholzen T; Gerdes J
J Cell Physiol; 2000 Mar; 182(3):311-22. PubMed ID: 10653597
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
[TBL] [Abstract][Full Text] [Related]
30. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients.
Wiesner FG; Magener A; Fasching PA; Wesse J; Bani MR; Rauh C; Jud S; Schrauder M; Loehberg CR; Beckmann MW; Hartmann A; Lux MP
Breast; 2009 Apr; 18(2):135-41. PubMed ID: 19342238
[TBL] [Abstract][Full Text] [Related]
31. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group.
Fradet Y; Tardif M; Bourget L; Robert J
Cancer Res; 1990 Jan; 50(2):432-7. PubMed ID: 2295082
[TBL] [Abstract][Full Text] [Related]
32. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity.
Müller V; Stahmann N; Riethdorf S; Rau T; Zabel T; Goetz A; Jänicke F; Pantel K
Clin Cancer Res; 2005 May; 11(10):3678-85. PubMed ID: 15897564
[TBL] [Abstract][Full Text] [Related]
34. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
Bray KR; Koda JE; Gaur PK
Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
[TBL] [Abstract][Full Text] [Related]
35. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.
Tan P; Cady B; Wanner M; Worland P; Cukor B; Magi-Galluzzi C; Lavin P; Draetta G; Pagano M; Loda M
Cancer Res; 1997 Apr; 57(7):1259-63. PubMed ID: 9102210
[TBL] [Abstract][Full Text] [Related]
36. Proliferative activity (Ki-67), WT p53, Bcl-2 expression and their relationship to the tumor grade, in invasive ductal breast carcinomas.
Kalogeraki A; Garbagnati F; Santinami M; Zoras O
In Vivo; 2002; 16(2):141-4. PubMed ID: 12073773
[TBL] [Abstract][Full Text] [Related]
37. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.
Sittel C; Eckel HE; Damm M; von Pritzbuer E; Kvasnicka HM
Laryngoscope; 2000 Jun; 110(6):1012-7. PubMed ID: 10852523
[TBL] [Abstract][Full Text] [Related]
38. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers.
Simony J; Pujol JL; Radal M; Ursule E; Michel FB; Pujol H
Cancer Res; 1990 Jul; 50(14):4382-7. PubMed ID: 2163748
[TBL] [Abstract][Full Text] [Related]
39. Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7).
Guillaud P; du Manoir S; Seigneurin D
Anal Cell Pathol; 1989 Feb; 1(1):25-39. PubMed ID: 2488698
[TBL] [Abstract][Full Text] [Related]
40. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
